Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
NCT07686081
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis (UC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Vanda Pharmaceuticals
- Last updated on ClinicalTrials.gov
- August 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Vanda Investigational Site · Chula Vista, CA
Tennessee · 1
- Vanda Investigational Site · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.